Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
30 Sep 2020 02:00 PM
RNS
Price Monitoring Extension
30 Sep 2020 10:35 AM
RNS
Launch of SARS-CoV-2 BAMS Research Test
29 Sep 2020 07:00 AM
RNS
Appointment of Joint Broker
28 Sep 2020 09:00 AM
RNS
Price Monitoring Extension
28 Sep 2020 07:00 AM
RNS
Interim Results for the Period Ended 30 June 2020
24 Sep 2020 07:00 AM
RNS
Update on Integumen Collaboration
14 Sep 2020 07:00 AM
RNS
Notice of Results and Investor Presentation
07 Sep 2020 07:00 AM
RNS
Avacta to Launch SARS-CoV-2 ELISA Laboratory Test
02 Sep 2020 07:00 AM
RNS
Expansion of COVID-19 Test Manufacturing Capacity
20 Aug 2020 04:45 PM
RNS
Issue of Equity
19 Aug 2020 04:41 PM
RNS
Second Price Monitoring Extn
19 Aug 2020 04:36 PM
RNS
Price Monitoring Extension
19 Aug 2020 02:05 PM
RNS
Second Price Monitoring Extn
19 Aug 2020 02:00 PM
RNS
Price Monitoring Extension
18 Aug 2020 03:30 PM
RNS
Issue of Equity
18 Aug 2020 07:00 AM
RNS
Expanded Partnership with LG Chem Life Sciences
17 Aug 2020 07:00 AM
RNS
Clarification Regarding Medusa 19 Antibody Test
11 Aug 2020 09:30 AM
RNS
Holding(s) in Company
11 Aug 2020 07:00 AM
RNS
Therapeutics Chief Development Officer Appointment
07 Aug 2020 07:00 AM
RNS
SARS-CoV-2 Antigen Test Clinical Collaboration
06 Aug 2020 07:00 AM
RNS
COVID-19 Rapid Antigen Test Manufacturing Partner
29 Jul 2020 07:00 AM
RNS
Expanded Partnership with Daewoong Pharmaceutical
22 Jul 2020 07:00 AM
RNS
Update on Adeptrix COVID-19 Diagnostic Test
17 Jul 2020 04:41 PM
RNS
Second Price Monitoring Extn
17 Jul 2020 04:35 PM
RNS
Price Monitoring Extension
13 Jul 2020 07:00 AM
RNS
Collaboration with Integumen plc
07 Jul 2020 02:06 PM
RNS
Issue of Equity
03 Jul 2020 04:41 PM
RNS
Second Price Monitoring Extn
03 Jul 2020 04:35 PM
RNS
Price Monitoring Extension
24 Jun 2020 11:15 AM
RNS
Result of General Meeting
24 Jun 2020 07:00 AM
RNS
Update on COVID-19 Test Development Partnership
22 Jun 2020 02:52 PM
RNS
Result of AGM
18 Jun 2020 07:00 AM
RNS
Update on Affimer® Therapy for COVID-19 Infection
17 Jun 2020 11:05 AM
RNS
Second Price Monitoring Extn
17 Jun 2020 11:00 AM
RNS
Price Monitoring Extension
15 Jun 2020 04:41 PM
RNS
Second Price Monitoring Extn
15 Jun 2020 04:36 PM
RNS
Price Monitoring Extension
15 Jun 2020 02:05 PM
RNS
Second Price Monitoring Extn
15 Jun 2020 02:00 PM
RNS
Price Monitoring Extension
15 Jun 2020 11:05 AM
RNS
Second Price Monitoring Extn
15 Jun 2020 11:00 AM
RNS
Price Monitoring Extension
12 Jun 2020 07:00 AM
RNS
Holding(s) in Company
10 Jun 2020 06:35 PM
RNS
Holding(s) in Company
09 Jun 2020 07:01 AM
RNS
Investor Presentation
09 Jun 2020 07:00 AM
RNS
Update on COVID-19 Test Development with Adeptrix
08 Jun 2020 04:15 PM
RNS
Posting of Circular and Notice of General Meeting
04 Jun 2020 05:16 PM
RNS
Director/PDMR Shareholding
04 Jun 2020 05:15 PM
RNS
Result of Fundraising
04 Jun 2020 12:30 PM
RNS
Increase in Fundraising
04 Jun 2020 11:05 AM
RNS
Second Price Monitoring Extn

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100